Key Highlights
- Cellectis shares closed down 41% at $1.83.
- The company announced a strategic pivot toward in vivo gene-editing programs.
- Focus shifts to .HEAL-101 for APOC3 in severe hypertriglyceridemia and .HEAL-201 for PCSK9 in severe hypercholesterolemia.
- Cellectis is discontinuing clinical work on lasme-cel and eti-cel to stretch its cash runway into the second half of 2028.
Cellectis S.A. (NASDAQ: CLLS) shares closed down 41% at $1.83 after the company announced a strategic pivot toward in vivo gene-editing programs, focusing resources on .HEAL-101 for APOC3 in severe hypertriglyceridemia and .HEAL-201 for PCSK9 in severe hypercholesterolemia.
What Happened
Initial Phase 1 readouts for the two programs are expected in the second half of 2027 and first half of 2028, respectively, while the company is discontinuing clinical work on lasme-cel and eti-cel to stretch its operational cash runway into the second half of 2028.
Market Reaction
Shares fell sharply as investors responded to the discontinuation of two existing clinical-stage programs, even as the company redirected focus and Capital toward its newer in vivo gene-editing pipeline.
Outlook
Initial Phase 1 readouts for .HEAL-101, expected in the second half of 2027, and .HEAL-201, expected in the first half of 2028, represent the next major disclosed milestones for Cellectis's newly prioritized pipeline.
FAQs
Q: Why did Cellectis shares fall 41%?
A: Shares fell after the company announced a strategic pivot to in vivo gene editing, discontinuing clinical work on lasme-cel and eti-cel.
Q: What are Cellectis's new lead programs?
A: .HEAL-101 for APOC3 in severe hypertriglyceridemia and .HEAL-201 for PCSK9 in severe hypercholesterolemia.
Q: When are initial Phase 1 readouts expected?
A: The second half of 2027 for .HEAL-101 and the first half of 2028 for .HEAL-201.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.